Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease

Authors not listed

University of California, Davis · 2022

Abstract

Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scores and blood and cerebrospinal fluid (CSF) markers of neuroinflammation. This pilot study will provide an estimate of treatment effect size on cognitive trajectory, daily function, and brain atrophy.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Anonymous. (2022). Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease. <em>University of California, Davis</em>. https://clinicaltrials.gov/study/NCT04804241
Vancouver
Anonymous. Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease. University of California, Davis. 2022.
BibTeX
@misc{anon2022Proofo, title = {Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease}, author = {Anonymous}, journal = {University of California, Davis}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings